文献速递血脂与心血管预防

增加他汀处方率的干预措施在心血管病一级预防中的效果:随机临床试验系统综述

Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials.
PubMed 文献 · JAMA Cardiol · 2019-01-01

该系统综述纳入20项随机临床试验(共109 807例无心血管病史成人),评估患者导向和医生导向干预对提高他汀处方率的效果。8项试验报告他汀处方率显著增加,绝对效应量从4.2%(95%CI 2.2%-6.4%)到23%(95%CI 7.3%-38.9%),患者教育干预最常有效,而缺乏动态患者风险或更新治疗建议的医生教育项目效果较差。

要点

  • 患者教育干预在7项试验中4项显示提高他汀处方率,较单纯医生教育更有前景。
  • 电子决策支持联合审计反馈的两项试验均整体有效。
  • 缺乏动态患者风险信息或更新治疗建议的医生教育项目通常效果较差。

核心结论

  • 多种干预措施可提高他汀处方率,患者教育干预比单纯医生教育更有前景。
  • 提供个性化心血管风险信息、动态决策支持工具或多组分审计反馈的干预更有效。

研究设计与样本

  • 系统综述,检索PubMed、Embase和Cochrane Library 2000年1月至2019年5月发表的随机临床试验。
  • 共纳入20项研究,涉及109 807例无心血管病史的成人。

主要发现

  • 8项试验报告他汀处方率显著增加,绝对效应量范围4.2%(95%CI 2.2%-6.4%)至23%(95%CI 7.3%-38.9%)。
  • 有效试验的比值比范围1.29(95%CI 1.01-1.66)至11.8(95%CI 8.8-15.9)。
  • 患者教育干预在7项试验中4项有效;两项电子决策支持联合审计反馈的试验均整体有效。
  • 缺乏动态患者风险或更新治疗建议的医生教育项目通常效果较差。

临床怎么用

  • 可优先考虑患者教育、个性化心血管风险信息、动态决策支持工具及审计反馈等多组分干预以提高他汀处方率。

局限性

  • 纳入试验的干预措施和结局存在异质性。
  • 对各研究偏倚风险仅作定性评估,并绘制漏斗图进一步评估发表偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Statins are a cornerstone medication in cardiovascular disease prevention, but their use in clinical practice remains suboptimal, with less than half of people who are indicated for statins actually taking the medication. OBJECTIVE: To perform a systematic review and synthesis of the literature on patient-oriented and physician-oriented interventions aimed at increasing statin-prescribing rates in adults without a history of cardiovascular disease. EVIDENCE REVIEW: PubMed, Embase, and the Cochrane Library were searched for randomized clinical trials published between January 2000 and May 2019. Data abstraction was performed using the Cochrane Public Health Review Group's data collection template, and a narrative synthesis of study results was conducted. The risk of bias in each study was qualitatively assessed, and a funnel plot was created to further evaluate the risk of publication bias. FINDINGS: Among 7948 citations and 128 full-text articles reviewed, 20 studies (of 109 807 patients) were included in the review. Eight trials reported a statistically significant increases in statin-prescribing rates. Among the effective trials, absolute effect sizes ranged from 4.2% (95% CI, 2.2%-6.4%) to 23% (95% CI, 7.3%-38.9%) and odds ratios from 1.29 (95% CI, 1.01-1.66) to 11.8 (95% CI, 8.8-15.9). Patient-education initiatives were the most commonly effective intervention, with 4 of 7 trials indicating increases in statin-prescribing rates. Two trials combined electronic decision-support tools with audit-and-feedback systems, both of which were effective overall. Physician-education programs without dynamic input regarding patient risk or updated treatment recommendations were generally found to be less effective. CONCLUSIONS AND RELEVANCE: While heterogeneous in their interventions and outcomes, a number of interventions have demonstrated increases in statin-prescribing rates, with patient-education initiatives demonstrating more promising results than those focused on physician education alone. As opposed to more education about generic recommendations, tailored patient-focused and physician-focused interventions were more effective when they provided personalized cardiovascular risk information, dynamic decision-support tools, or audit-and-feedback reports in a multicomponent program. There are a number of modestly successful approaches to implement increases in rates of statin prescribing, a proven yet underused cardiovascular disease prevention class of therapy.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Sparrow RT, Khan AM, Ferreira-Legere LE, et al. Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials. JAMA Cardiol. 2019. PMID: 31461127. doi:10.1001/jamacardio.2019.3066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。